

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

NOVARTIS PHARMACEUTICALS	)	
CORPORATION,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. 19-2053-LPS
	)	
DR. REDDY'S LABORATORIES, INC.,	)	
DR. REDDY'S LABORATORIES, LTD.,	)	
HETERO USA INC., HETERO LABS	)	
LIMITED, HETERO LABS LIMITED	)	
UNIT III, MSN PHARMACEUTICALS	)	
INC., MSN LABORATORIES PRIVATE	)	
LIMITED, MSN LIFE SCIENCES	)	
PRIVATE LIMITED, MYLAN	)	
PHARMACEUTICALS INC., MYLAN	)	
INC., MYLAN LABORATORIES	)	
LIMITED, NOVUGEN PHARMA	)	
(MALAYSIA) SDN. BHD., ZYDUS	)	
PHARMACEUTICALS (USA) INC.,	)	
CADILA HEALTHCARE LTD.,	)	
	)	
Defendants.	)	

**STIPULATION AND [PROPOSED] ORDER**

This stipulation is made by and between Novartis Pharmaceuticals Corporation ("Plaintiff"); and Mylan Pharmeceuticals Inc., Mylan Inc., and Mylan Laboratories Limited (collectively, "the Mylan Defendants").

WHEREAS Plaintiff on October 29, 2019 filed suit against the Mylan Defendants in the above-captioned case (the "Delaware Action", defined to include this action, any action that may result from case consolidation, or any lead case with which that action is associated);

WHEREAS Plaintiff on October 30, 2019 brought a concurrent action against the Mylan Defendants in the U.S. District Court for the Northern District of West Virginia having Civil Action No. 19-cv-201-IMK (the "West Virginia Action");

WHEREAS, in MDL No. 2930, Plaintiff has moved the Judicial Panel on Multidistrict Litigation (the “MDL Panel”) to transfer and consolidate the West Virginia Action for pretrial proceedings in Delaware;

WHEREAS, the Mylan Defendants have filed a notice of non-opposition in MDL No. 2930 to Plaintiff’s motion to transfer and consolidate the West Virginia Action in Delaware for pretrial proceedings; and

NOW THEREFORE Plaintiff and the Mylan Defendants, subject to the approval of the Court, stipulate and agree as follows:

1. Plaintiff hereby dismisses without prejudice its claims against the Mylan Defendants in the Delaware Action pursuant to Fed. R. Civ. P. 41(a)(2).

This 5<sup>th</sup> day of February, 2020

/s/ Daniel M. Silver

Daniel M. Silver (#4758)  
Alexandra M. Joyce (#6423)  
MCCARTER & ENGLISH, LLP  
Renaissance Centre  
405 N. King Street, 8th Floor  
Wilmington, DE 19801  
(302) 984-6300  
dsilver@mccarter.com  
ajoyce@mccarter.com

*Attorneys for Plaintiff Novartis  
Pharmaceuticals Corporation*

/s/ David E. Moore

David E. Moore (#3983)  
Bindu A. Palapura (#5370)  
POTTER ANDERSON & CARROON LLP  
Hercules Plaza, 6th Floor  
1313 North Market Street  
Wilmington, DE 19801  
(302) 984-6000  
dmoore@potteranderson.com  
bpalapura@potteranderson.com

*Attorneys for Mylan Pharmaceuticals Inc.,  
Mylan Inc. and Mylan Laboratories Limited*

IT IS SO ORDERED this \_\_\_\_ day of February, 2020.

\_\_\_\_\_  
U.S.D.J.